Trials / Not Yet Recruiting
Not Yet RecruitingNCT06635772
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
A Randomized, Multicenter, Open-label, Active-control Study of the Efficacy and Safety of HS-10390 for the Treatment of Immunoglobulin a Nephropathy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Hansoh BioMedical R&D Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of HS-10390 in subjects with primary IgA nephropathy, and explore the optimal dose for the treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-10390 | HS-10390 will be administered daily |
| DRUG | Irbesartan | Irbesartan will be administered daily as a 150-mg oral tablet. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2025-12-01
- Completion
- 2026-04-30
- First posted
- 2024-10-10
- Last updated
- 2024-10-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06635772. Inclusion in this directory is not an endorsement.